SKIP000382
SKIP ID SKIP000382
Organism(En) -
Organism(Ja) -
Cell Type(En) -
Cell Type(Ja) -
Cell Tissue(En) -
Cell Tissue(Ja) -
Cell Origin Diseased
Cell Name 1(En) HPS0244
Cell Name 1(Ja) HPS0244
Cell Name 2(En) -
Cell Name 2(Ja) -
Disease Name 1(Ja) X連鎖αサラセミア·精神遅滞(ATR-X)症候群
ICD Code 1 D560
Disease Name 1(En) X-Linked alpha-Thalassemia, Mental Retardation Syndrome (ATR-X syndrome)
OMIM1 301040
Disease Name 2(Ja) -
ICD Code 2 -
Disease Name 2(En) -
OMIM 2 -
Disease Name 3(Ja) -
ICD Code 3 -
Disease Name 3(En) -
OMIM 3 -
Age -
Age Range --
Sex --
Race(En) -
Race(Ja) -
Genetic Diagnosis No
Not Detected No
Description(En) Disease specific iPS cell line derived from a patient : X-Linked alpha-Thalassemia, Mental Retardation Syndrome (ATR-X syndrome)
Description(Ja) 疾患特異的iPS細胞株。X連鎖alphaサラセミア·精神遅滞(ATR-X)症候群患者由来。
Cell Morphology human ES-like
Grade Research Grade
Vector Sendai virus
Transgene SeV18+HS-OCT3/4/TSdeltaF, SeV18+HS-SOX2/TSdeltaF, SeV18+HS-KLF4/TSdeltaF, SeV18(HNL)c-MYCQC/TSdeltaF
Adhesiveness -
Feeder Yes
Feeder Cell MEF (X-rays:5000R or MMC) 3-5x10^(5) cells/60mm dish
Medium DMEM/HamF12(2mM L-Glutamine)+20%KSR+0.1mM NEAA+0.1mM 2-Mercaptoethanol+5ng/ml human bFGF
Genome Editing -
CO2 -
Mycoplasma -
Detection of Contaminants Mycoplasma -
Pluripotent Markers -
Pluripotent Markers Assay -
in vitro Differentiation -
in vitro Differentiation Assay -
in vivo Differentiation -
in vivo Differentiation Assay -
Other 1 Assay -
Other 1 Assay Method -
Other 2 Assay -
Other 2 Assay Method -
Other 3 Assay -
Other 3 Assay Method -
Karyotype -
Karyotype Assay -
Remaining Vector Detection -
Remaining Vector Detection Assay -
STR -
HLA -
Stem Cell Transcriptome analysis -
Stem Cell Transcriptome analysis Assay -
Author Name(En) Apply to RIKEN
Author Name(Ja) 理研に問い合わせ
Author Organization(En) Apply to RIKEN
Author Organization(Ja) 理研に問い合わせ
Author Contact Email -
PI Organization(En) Apply to RIKEN
PI Organization(Ja) 理研に問い合わせ
PI Name(En) Apply to RIKEN
PI Name(Ja) 理研に問い合わせ
PI Contact Email -
Availability Available
Provider Organization(En) RIKEN BioResource Center -CELL BANK-
Provider Organization(Ja) 理化学研究所 バイオリソースセンター 細胞材料開発室
Provider Email cellips[at]brc[dot]riken[dot]jp
Provider URL http://cell.brc.riken.jp/
Ethical Statement(En) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. Contact Us : cellips@brc.riken.jp
Ethical Statement(Ja) 寄託者の承諾等の特殊な手続きが必要。先ずは、理研細胞バンクにお問い合わせください(cellips@brc.riken.jp)。
Terms of Use(En) 1)The guideline must be observed when using SeV-iPS cells. 2)In relation to the for-profit organizations, please access to the following URL and consult 'iPS Academia Japan, Inc.' (http://ips-cell.net/e/index.php) prior to the utilization of iPS cells. 3)The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the APPROVER. 4)This cell line should be used as a collaboration work with the depositor for two years after (December, 2015) disclosure of this cell line.
Terms of Use(Ja) 1) ディナベック株式会社とBRCとの「センダイウイルスベクタートランスファーライセンス学術研究向け覚書」 を確認すること。2) 非営利機関以外の利用者は事前にiPSアカデミアジャパン株式会社(http://ips-cell.net/j/index.php)から確認書を得ること。3) 寄託者から承諾を得ること。4) 公開から2年間 (2015年12月まで) は共同研究とすること。
PubMed ID -
DOI -
Title -
Authors -
Journal -
Year -
Volume -
Issue -
Pages -
URL -
Free input -
Note -